Beijing QL Biopharmaceutical Co., Ltd.
Clinical trials sponsored by Beijing QL Biopharmaceutical Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Kidney patients get first look at new obesity drug Results expected Dec 2026 (estimated)
- New obesity drug ZT002 tested for safety with other medications Results expected Dec 2026 (estimated)
- New Weight-Loss pill ZT006 enters Mid-Stage trial Results expected Dec 2026 (estimated)
- New drug ZT003 tested for safety in first human trial Results expected Dec 2026 (estimated)
- Heart safety check for new Weight-Loss drug candidate Results expected Jan 2027 (estimated)
-
Can a new Weight-Loss shot replace wegovy without stomach trouble?
Disease control Not yet recruitingResearchers are testing whether adults with obesity can safely switch from semaglutide (Wegovy) to an experimental drug called zovaglutide. The trial enrolls 210 people aged 18 to 75 with a BMI of at least 28 who do not have diabetes. Participants first receive semaglutide inject…
Phase 2 • Sponsor: Beijing QL Biopharmaceutical Co.,Ltd • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Heart safety check for new Weight-Loss drug candidate
Knowledge-focused Not yet recruitingThis phase 1 study investigates whether ZT002 (zovaglutide), an experimental injectable drug given every two weeks, affects the heart's electrical activity in overweight or obese adults. Researchers compare changes in the QT interval—a measure of heart rhythm—between those receiv…
Phase 1 • Sponsor: Beijing QL Biopharmaceutical Co.,Ltd • Aim: Knowledge-focused
Last updated Jul 15, 2026 00:00 UTC